This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merck KGaA

Drug Names(s): mitoxantrone

Description: Novantrone is a cytotoxic anti-cancer agent that is used to treat certain types of leukemia and advanced prostate cancer as well as certain forms of multiple sclerosis. Novantrone impairs cancer cell proliferation by intercalating into specific regions of DNA, interfering with RNA structure, and inhibiting an enzyme that repairs damaged DNA (topoisomerase II).

Deal Structure: Novantrone was an Immunex drug acquired by Amgen. Wyeth markets Novantrone outside the United States, where it has generic competition.

Amgen licensed U.S. rights to Novantrone to Serono in November 2002. Serono licensed U.S. oncology rights to OSI in March 2003. OSI will pay Serono $55 million plus maintenance fees in return for commissions on net sales. Serono will continue to market Novantrone for multiple sclerosis.

In January 2007, the acquisition of Serono S.A. (now Merck Serono S.A.) by Merck KGaA and the integration of the business with the former Merck KGaA Ethicals Division was completed. Merck Serono is now the division of Merck KGaA which specializes in prescription pharmaceuticals. Its North American business operates in the United States and Canada under EMD Serono.

In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19...See full deal structure in Biomedtracker

Partners: Pfizer Inc. Astellas Pharma, Inc.

Novantrone News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug